---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-118575"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:27:29.446242+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Onconova reports Q3 net loss $5.4M; plans Phase 1/2a narazaciclib trial in endometrial cancer in 1Q23

## Summary
- Net loss of $5.4M ($0.26/share) vs $3.5M ($0.22) in Q3 2021; R&D expenses rose to $3.6M from $1.8M.
- Cash and equivalents $42.6M as of Sep 30, 2022, down from $55.1M at Dec 31, 2021; expects to fund operations into 2024.
- Plans to initiate Phase 1/2a trial of narazaciclib + letrozole in recurrent LGEEC in 1Q23; preliminary data expected 4Q23.
- Rigosertib/nivolumab trial in KRAS-mutated NSCLC showed one complete response and two partial responses in 14 evaluable patients.
- Rigosertib investigator-sponsored trials continue; Phase 2 melanoma trial on track for initiation.

## SEC filing metadata
- accession: 0001104659-22-118575
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/0001104659-22-118575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/tm2230479d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-118575
- JSON: https://secwatch.observer/filing/0001104659-22-118575.json
- Plain text: https://secwatch.observer/filing/0001104659-22-118575.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Onconova Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465922118575/0001104659-22-118575-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.